Tau Pipeline Enabling Program V (T-PEP) supports researchers developing therapeutic candidates targeting tau or related mechanisms to advance potential disease-modifying treatments for tauopathies.
Funder: Alzheimer's Association
Due Dates (Anticipated): May 2027 (LOI) | August 2027 (Full application)
Funding Amounts: Up to $750,000 for up to 2 years
Summary: Supports milestone-driven development of therapeutic candidates targeting tau or tau-related mechanisms in tauopathies.
Key Information: Projects with any compound or target discovery component are not responsive.
The Tau Pipeline Enabling Program V (T-PEP) is jointly funded by the Alzheimer's Association and the Rainwater Charitable Foundation. It supports translational research advancing potential disease-modifying therapies for tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The program bridges the gap between academia-derived therapeutic ideas and pharmaceutical companies seeking candidates for human trials.
Funding targets development candidate selection, lead optimization, in vivo proof-of-concept, and IND-enabling studies, including cGMP scale-up/manufacture and animal efficacy studies. Projects may address tau toxicity directly or related mechanisms such as neuroinflammation, mitochondrial dysfunction, microtubule stability, and axonal transport. Work on related mechanisms must explain how it will prevent, reduce, remove, or otherwise mitigate tau toxicity. Interdisciplinary teams, contract research organizations, and outside consultants are encouraged.